**Strong trader consensus behind the 93.2% implied probability of no new coronavirus pandemic in 2026 reflects persistently low global SARS-CoV-2 transmission and the WHO’s moderate public health risk assessment through mid-2026.** Official surveillance shows stable, low test positivity (typically 1–4% in recent weeks), with JN.1-descendant variants such as NB.1.8.1 and XFG circulating alongside BA.3.2 without evidence of rapid dominance, increased severity, or widespread severe outcomes. Hybrid population immunity from prior infection and vaccination continues to limit progression to pandemic-level disease, while MERS-CoV reports remain minimal and no novel coronavirus spillover has triggered international concern. Genomic and wastewater monitoring by agencies like the CDC and WHO provides ongoing early detection. Realistic challenges include emergence of a variant with substantially enhanced transmissibility plus virulence, or an unexpected zoonotic event meeting WHO pandemic criteria, though current data indicate these remain low-probability outcomes before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoNuova pandemia di coronavirus nel 2026?
Sì
$25,081 Vol.
$25,081 Vol.
Sì
$25,081 Vol.
$25,081 Vol.
The resolution source will be official announcements from the World Health Organization.
Mercato aperto: Jan 6, 2026, 2:40 PM ET
Risolutore
0x65070BE91...The resolution source will be official announcements from the World Health Organization.
Risolutore
0x65070BE91...**Strong trader consensus behind the 93.2% implied probability of no new coronavirus pandemic in 2026 reflects persistently low global SARS-CoV-2 transmission and the WHO’s moderate public health risk assessment through mid-2026.** Official surveillance shows stable, low test positivity (typically 1–4% in recent weeks), with JN.1-descendant variants such as NB.1.8.1 and XFG circulating alongside BA.3.2 without evidence of rapid dominance, increased severity, or widespread severe outcomes. Hybrid population immunity from prior infection and vaccination continues to limit progression to pandemic-level disease, while MERS-CoV reports remain minimal and no novel coronavirus spillover has triggered international concern. Genomic and wastewater monitoring by agencies like the CDC and WHO provides ongoing early detection. Realistic challenges include emergence of a variant with substantially enhanced transmissibility plus virulence, or an unexpected zoonotic event meeting WHO pandemic criteria, though current data indicate these remain low-probability outcomes before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato



Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti